Findings of Research Misconduct, 18837 [2010-8387]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 70 / Tuesday, April 13, 2010 / Notices
falsifications/fabrications were the
underlying reason for the retraction/
corrections.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
John Dahlberg,
Director, Division of Investigative Oversight,
Office of Research Integrity.
[FR Doc. 2010–8386 Filed 4–12–10; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
sroberts on DSKD5P82C1PROD with NOTICES
ACTION:
SUMMARY: Notice is hereby given that
the Office of Research Integrity (ORI)
and the Assistant Secretary for Health
have taken final action in the following
case:
Boris Cheskis, Ph.D., Wyeth
Pharmaceuticals: Based on the report of
an investigation conducted by Wyeth
Pharmaceuticals and additional analysis
conducted by ORI in its oversight
review, ORI found that Boris Cheskis,
Ph.D., former senior scientist, Discovery
Research, Women’s Health, Wyeth
Pharmaceuticals, engaged in research
misconduct in grant applications 1 R01
DK072026–01 and 1 R01 DK072026–
01A2 submitted to the National Institute
of Diabetes and Digestive and Kidney
Diseases (NIDDK), NIH.
Specifically, ORI found that:
• The Respondent engaged in
misconduct in science, 42 CFR 50.102,
in NIDDK, NIH, grant application 1 R01
DK072026–01, ‘‘MNAR Crosstalk with
Steroid Receptors,’’ submitted to NIH on
September 28, 2004, by intentionally
falsifying Figures 5 and 6.
• The Respondent engaged in
research misconduct, 42 CFR 93.103, in
NIDDK, NIH, grant application 1 R01
DK072026–01A2, ‘‘MNAR Crosstalk
with Steroid Receptors,’’ submitted to
NIH on November 9, 2005, by
intentionally falsifying Figures 6 and 9.
Dr. Cheskis’ research was in an area
of research (estrogen receptors and
modulation of nongenomic
phosphorylation cascades) that is of
importance to women’s health. Dr.
Cheskis’ team identified an adapter
protein, MNAR, that coordinates
interactions between certain nuclear
receptors, Src and PI3K and may play
VerDate Nov<24>2008
17:33 Apr 12, 2010
Jkt 220001
important roles in regulation of cell
proliferation and survival.
Both Dr. Cheskis and the U.S. Public
Health Service (PHS) were desirous of
concluding this matter without further
expense of time and other resources. Dr.
Cheskis neither admits nor denies that
ORI’s findings represent findings of
research misconduct. The settlement is
not an admission of liability on the part
of the Respondent.
Dr. Cheskis has entered into a
Voluntary Settlement Agreement. Dr.
Cheskis has voluntarily agreed, for a
period of two (2) years, beginning on
March 22, 2010:
(1) To exclude himself from serving in
any advisory capacity to PHS, including
but not limited to service on any PHS
advisory committee, board, and/or peer
review committee, or as a consultant;
(2) That any institution that submits
an application for PHS support for a
research project on which the
Respondent’s participation is proposed
or that uses him in any capacity on
PHS-supported research, or that submits
a report of PHS-funded research in
which he is involved, must concurrently
submit a plan for supervision of his
duties to the funding agency for
approval; the supervisory plan must be
designed to ensure the scientific
integrity of his research contribution;
respondent agreed that he will not
participate in any PHS-supported
research until such a supervisory plan is
submitted to ORI.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
John Dahlberg,
Director, Division of Investigative Oversight,
Office of Research Integrity.
[FR Doc. 2010–8387 Filed 4–12–10; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Office of Public Health and Science,
Office of Minority Health; Privacy Act
of 1974; Report of a New System of
Records
AGENCY: Department of Health and
Human Services, Office of the Secretary,
Office of Public Health and Science,
Office of Minority Health.
ACTION: Notice of a new Privacy Act
System of Records (SOR).
SUMMARY: In accordance with the
requirements of the Privacy Act, OMH
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
18837
proposes to establish a new system of
records entitled, ‘‘Minority Health
Information Service.’’ Under provisions
of 42 U.S.C. sec. 300u–6, the Office of
Minority Health (OMH) is charged with
maintaining a national minority health
resource center to (1) Facilitate
exchange of and access to information
related to health information,
promotion, services and education; (2)
assist in analysis of issues and problems
with regard to such matters; and (3)
provide technical assistance with regard
to the exchange of such information.
The primary purpose of this system is
to collect and facilitate distribution of
minority health information to public
and professional audiences. In support
of this purpose, this system maintains
individually identifiable information
concerning individuals voluntarily
participating in OMH health campaigns
and technical assistance programs, and
concerning information requested by
individually identifiable customers that
is maintained to facilitate order tracking
and customer service.
DATES: Effective Dates: This notice will
become effective 30 days from the date
of publication of the notice unless
modified by a subsequent notice making
changes in response to public
comments. Although the Privacy Act
requires only that OMH provide an
opportunity for interested persons to
comment on the proposed routine uses,
OMH invites comments on all portions
of this notice.
FOR FURTHER INFORMATION CONTACT:
Blake Crawford, Director, Division of
Information and Education, Office of
Minority Health, 1101 Wootton
Parkway, Suite 600, Rockville, MD
20852. He can be reached by telephone
at 240–453–6905 or via e-mail at
blake.crawford@hhs.gov.
SUPPLEMENTARY INFORMATION: Generally,
OMH distributes a variety of
information via e-mail newsletter,
maintains a Resource Persons Network
of public and private health experts,
plans and implements health campaigns
and leads national initiatives with
federal and nonfederal partners,
conducts leadership development
programs, provides capacity
development and technical assistance
services to community organizations
and government agencies and provides
information, literature and statistical
data in response to public inquiries. The
Minority Health Information Service
supports the mission of the OMH
Resource Center (OMHRC) to function
as a help desk and technical assistance
service for the public and an
organization that assists OMH in
implementing national initiatives and
E:\FR\FM\13APN1.SGM
13APN1
]]>Agencies
[Federal Register Volume 75, Number 70 (Tuesday, April 13, 2010)]
[Notices]
[Page 18837]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-8387]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) and the Assistant Secretary for Health have taken final action in
the following case:
Boris Cheskis, Ph.D., Wyeth Pharmaceuticals: Based on the report of
an investigation conducted by Wyeth Pharmaceuticals and additional
analysis conducted by ORI in its oversight review, ORI found that Boris
Cheskis, Ph.D., former senior scientist, Discovery Research, Women's
Health, Wyeth Pharmaceuticals, engaged in research misconduct in grant
applications 1 R01 DK072026-01 and 1 R01 DK072026-01A2 submitted to the
National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), NIH.
Specifically, ORI found that:
The Respondent engaged in misconduct in science, 42 CFR
50.102, in NIDDK, NIH, grant application 1 R01 DK072026-01, ``MNAR
Crosstalk with Steroid Receptors,'' submitted to NIH on September 28,
2004, by intentionally falsifying Figures 5 and 6.
The Respondent engaged in research misconduct, 42 CFR
93.103, in NIDDK, NIH, grant application 1 R01 DK072026-01A2, ``MNAR
Crosstalk with Steroid Receptors,'' submitted to NIH on November 9,
2005, by intentionally falsifying Figures 6 and 9.
Dr. Cheskis' research was in an area of research (estrogen
receptors and modulation of nongenomic phosphorylation cascades) that
is of importance to women's health. Dr. Cheskis' team identified an
adapter protein, MNAR, that coordinates interactions between certain
nuclear receptors, Src and PI3K and may play important roles in
regulation of cell proliferation and survival.
Both Dr. Cheskis and the U.S. Public Health Service (PHS) were
desirous of concluding this matter without further expense of time and
other resources. Dr. Cheskis neither admits nor denies that ORI's
findings represent findings of research misconduct. The settlement is
not an admission of liability on the part of the Respondent.
Dr. Cheskis has entered into a Voluntary Settlement Agreement. Dr.
Cheskis has voluntarily agreed, for a period of two (2) years,
beginning on March 22, 2010:
(1) To exclude himself from serving in any advisory capacity to
PHS, including but not limited to service on any PHS advisory
committee, board, and/or peer review committee, or as a consultant;
(2) That any institution that submits an application for PHS
support for a research project on which the Respondent's participation
is proposed or that uses him in any capacity on PHS-supported research,
or that submits a report of PHS-funded research in which he is
involved, must concurrently submit a plan for supervision of his duties
to the funding agency for approval; the supervisory plan must be
designed to ensure the scientific integrity of his research
contribution; respondent agreed that he will not participate in any
PHS-supported research until such a supervisory plan is submitted to
ORI.
FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453-8800.
John Dahlberg,
Director, Division of Investigative Oversight, Office of Research
Integrity.
[FR Doc. 2010-8387 Filed 4-12-10; 8:45 am]
BILLING CODE 4150-31-P
